Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant

References

• Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results From the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16–4984, NSDUH Series H-51). [ cited 2017May9]. Available from: https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2015/NSDUH-FFR1-2015/NSDUH-FFR1-2015.pdf.
   Google Scholar
• Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310(6):591–608.
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(02):155–162.
   PubMed Web of Science ®Google Scholar
• Crismon ML, Trivedi M, Pigott TA, et al. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry. 1999;60(3):142–156.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorders. Washington, DC: American Psychiatric Association, 2010.
   Google Scholar
• Santaguida P, MacQueen G, Keshavarz H, et al. Treatment for depression after unsatisfactory response to SSRIs. Comparative effectiveness review no. 62 (AHRQ publication no. 12-EHC050-EF). [ cited 2019Oct7]. Available from: https://effectivehealthcare.ahrq.gov/products/depression-treatment-ssri/research
   Google Scholar
• Warden D, Rush AJ, Trivedi MH, et al. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007; 9(6): 449–459.
   PubMedGoogle Scholar
• Ahern E, Semkovska M. Cognitive functioning in the first-episode of major depressive disorder: a systematic review and meta-analysis. Neuropsychology. 2017;31(1):52–72.
   PubMed Web of Science ®Google Scholar
• Lee RS, Hermens DF, Porter MA, et al. A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. J Affect Disord. 2012;140(2):113–124.
   PubMed Web of Science ®Google Scholar
• McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011;31(2):180–186.
   PubMed Web of Science ®Google Scholar
• Shilyansky C, Williams LM, Gyurak A, et al. Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study. Lancet Psychiatry. 2016;3(5):425–435.
   PubMed Web of Science ®Google Scholar
• Pehrson AL, Leiser SC, Gulinello M, et al. Treatment of cognitive dysfunction in major depressive disorder–a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. Eur J Pharmacol. 2015;753:19–31.
   PubMed Web of Science ®Google Scholar
• Trintellix (vortioxetine). Full Prescribing Information, Takeda Pharmaceuticals America, Inc., Deerfield, IL, 2018.
   Google Scholar
• Citrome L. Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015;69(2):151–155.
   PubMed Web of Science ®Google Scholar
• Fetzima (levomilnacipran). Full Prescribing Information, Allergan USA, Inc., Irvine, CA, 2016.
   Google Scholar
• Viibryd (vilazodone hydrochloride). Full Prescribing Information, Allergan USA, Inc., Irvine, CA, 2017.
   Google Scholar
• Soini E, Hallinen T, Brignone M, et al. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert Rev Pharmacoecon Outcomes Res. 2017;17(3):293–302.
   PubMed Web of Science ®Google Scholar
• Choi SE, Brignone M, Cho SJ, et al. Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea. Expert Rev Pharmacoecon Outcomes Res. 2016;16(5):629–638.
   PubMed Web of Science ®Google Scholar
• Reid I, Cameron I, MacGillvray S. Depression: current approaches to assessment and treatment. Prescriber. 2014;25(12):16–20.
   Google Scholar
• Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry. 1991;52(Suppl):28–34.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Sanders GD. Cost-effectiveness analysis 2.0. N Engl J Med. 2017;376(3):203–205.
   PubMed Web of Science ®Google Scholar
• Zimovetz EA, Wolowacz SE, Classi PM, et al. Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review. Cost Eff Resour Alloc. 2012;10(1):1.
   PubMedGoogle Scholar
• Montgomery SA, Nielsen RZ, Poulsen LH, et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014;29:470–482.
   PubMed Web of Science ®Google Scholar
• Limosin F, Loze JY, Zylberman-Bouhassira M, et al. The course of depressive illness in general practice. Can J Psychiatry. 2004;49(2):119–123.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.
   PubMed Web of Science ®Google Scholar
• Asnis GM, Bose A, Gommoll CP, et al. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74(03):242–248.
   PubMedGoogle Scholar
• Bakish D, Bose A, Gommoll C, et al. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2014;39(1):40–49.
   PubMed Web of Science ®Google Scholar
• Citrome L. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant–what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2013;67(11):1089–1104.
   PubMed Web of Science ®Google Scholar
• Gommoll CP, Greenberg WM, Chen C. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder. J Drug Assess. 2014;3(1):10–19.
   PubMedGoogle Scholar
• Mago R, Mahajan R, Thase ME. Levomilnacipran: a newly approved drug for treatment of major depressive disorder. Expert Rev Clin Pharmacol. 2014;7(2):137–145.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Mansuy L, Ruth A, et al. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2013;74(04):363–369.
   PubMedGoogle Scholar
• Sambunaris A, Bose A, Gommoll CP, et al. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol. 2014;34(1):47–56.
   PubMed Web of Science ®Google Scholar
• Shiovitz T, Greenberg WM, Chen C, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and safety of levomilnacipran ER 40-120mg/day for prevention of relapse in patients with major depressive disorder. Innov Clin Neurosci. 2014;11:10–22.
   PubMedGoogle Scholar
• Croft HA, Pomara N, Gommoll C, et al. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2014;75(11):e1291–1298.
   PubMed Web of Science ®Google Scholar
• Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011;72(04):441–447.
   PubMed Web of Science ®Google Scholar
• Mathews M, Gommoll C, Chen D, et al. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2015;30(2):67–74.
   PubMed Web of Science ®Google Scholar
• Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(3):326–333.
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR, Zajecka J, Jacobson W, et al. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015;40(8):2025–2037.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Lophaven S, Olsen CK, A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557–1567.
   PubMed Web of Science ®Google Scholar
• Bet PM, Hugtenburg JG, Penninx BW, et al. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol. 2013;23(11):1443–1451.
   PubMed Web of Science ®Google Scholar
• EuroQol Group. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs. 2004;18(13):911–932.
   PubMed Web of Science ®Google Scholar
• Dixon S, Currie CJ, McEwan P. Utility values for obesity and preliminary analysis of the Health Outcomes Data Repository. Expert Rev Pharmacoecon Outcomes Res. 2004;4(6):657–665.
   PubMedGoogle Scholar
• Boulenger JP, Haro JM, Lamy FX, et al. The burden of treatment change in major depressive disorder: comparison of switch versus non-switch patients in the PERFORM study. Value Health. 2013;16(7):A543.
   Google Scholar
• Red Book: A Comprehensive, Consistent Drug Pricing Resource [online database]. [ cited 2017Mar3]. Available from: http://micromedex.com/products/product-suites/clinical-knowledge/redbook
   Google Scholar
• Schultz J, Joish V. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder. Psychiatr Serv. 2009;60(12):1604–1611.
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics of the US Department of Labor. Consumer Price Index-All Urban Consumers, US Medical Care Services. [ cited 2017May9]. Available from: https://data.bls.gov/cgi-bin/surveymost?cu
   Google Scholar
• Agency for Healthcare Research and Quality. Calculating the U.S. Population-Based EQ-5D Index Score. [ cited 2017Feb21]. Available from: https://archive.ahrq.gov/professionals/clinicians-providers/resources/rice/EQ5Dscore.html#weights
   Google Scholar
• Vieta E, Loft H, Florea I. Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder. Eur Neuropsychopharmacol. 2017;27(9):877–884.
   PubMed Web of Science ®Google Scholar
• US Centers for Medicare & Medicaid. Physician Fee Schedule. [ cited 2017May9]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-Relative-Value-Files-Items/RVU14A.html
   Google Scholar
• Baune BT, Brignone M, Larsen KG. Efficacy of vortioxetine versus other antidepressants on cognitive dysfunction in patients with major depressive disorder. Eur Neuropsychopharmacol. 2016;26:S470.
   Web of Science ®Google Scholar
• Baune B, Brignone M, Larsen KG. Efficacy of vortioxetine versus other antidepressants on cognitive dysfunction in patients with major depressive disorder. Presented at: 29th Annual US Psychiatric & Mental Health Congress; 2016 Oct 21–24; San Antonio, TX.
   Google Scholar
• Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–613.
   PubMed Web of Science ®Google Scholar
• Fischer JS, LaRocca NG, Miller DM, et al. Recent developments in the assessment of quality of life in Multiple Sclerosis (MS). Mult Scler. 1999;5(4):251–259.
   PubMed Web of Science ®Google Scholar
• Shin SY, Katz P, Julian L. Relationship between perceived cognitive dysfunction and objective neuropsychological performance in persons with rheumatoid arthritis. Arthritis Care Res. 2013;65(3):481–486.
   Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797.
   PubMed Web of Science ®Google Scholar
• Keyloun KR, Devine B. Estimating the cost-effectiveness of vortioxetine versus desvenlafaxine as first line therapy for mild to moderate major depressive disorder in remitted patients. Presented at: ISPOR 20th Annual International Meeting Research 2015; 2015May16–20; Philadelphia, PA.
   Google Scholar
• Baune BT, Brignone M, Larsen KG. A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int J Neuropsychopharmacol. 2018;21(2):97–107.
   PubMed Web of Science ®Google Scholar
• Lam RW, Kennedy SH, McLntyre RS, et al. Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment. Can J Psychiatry. 2014;59(12):649–654.
   PubMed Web of Science ®Google Scholar
• Bortolato B, Miskowiak KW, Kohler CA, et al. Cognitive remission: a novel objective for the treatment of major depression? BMC Med. 2016;14:9.
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine. Enabling discovery, development, and translation of treatments for cognitive dysfunction in depression: workshop summary. Washington, DC: Forum on Neuroscience and Nervous System Disorders, 2015.
   Google Scholar
• Wang PS, Beck AL, Berglund P, et al. Effects of major depression on moment-in-time work performance. Am J Psychiatry. 2004;161:1885–1891.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Vortioxetine for treating major depressive episodes. [ cited 2015Nov25]. Available from: https://www.nice.org.uk/guidance/ta367/resources/vortioxetine-for-treating-major-depressive-episodes-pdf–82602733813189
   Google Scholar
• CVS Health. Current and new approaches to making drugs more affordable [ cited 2019Feb13]. Available from: https://cvshealth.com/sites/default/files/cvs-health-current-and-new-approaches-to-making-drugs-more-affordable.pdf
   Google Scholar
• Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry. 2007;164(5):739–752.
   PubMed Web of Science ®Google Scholar